Study finds cancer mapping may solve puzzle of regional disease links

August 13, 2020

QUT researchers have used nationwide cancer mapping statistics to develop a new mathematical model so health professionals can further question patterns relating to the disease.

Epidemiologists use disease atlases to identify disease prevalence and mortality rates and QUT researchers say data could be expanded by including factors such as remoteness to investigate health inequalities.

QUT PhD student Farzana Jahan is the lead author of a study, published in the Royal Society Open Science, that used a statistical approach to reveal patterns of cancer incidence according to the "remoteness".

The study, which drew upon the Australian Cancer Atlas, considered cancers from geographical regions including major cities, inner regional, outer regional and remote areas.

Cancers having higher incidence in remote areas were head and neck, liver, lung, oesophageal for males and females and cervical and uterine cancers for females.

While in major cities, cancers more likely to have greater incidence include brain, myeloma, non-Hodgkin lymphoma, pancreatic, stomach, thyroid cancer for both sexes, kidney cancer for males, leukaemia, and ovarian cancer for females.

Some cancers more likely to occur in regional areas included bowel, melanoma for both males and females, kidney cancer for females, leukaemia, and prostate cancer for males.

Ms Jahan said the research was an attempt to create a method by which any available disease maps or summary disease measures can be further modelled to "unmask new insights about health and medical issues" without having to go back to the individual health records.

"Our research provides a method for further analysing information that goes beyond the scope of disease summaries," Ms Jahan said.

Dr Susanna Cramb, a biostatistician and epidemiologist based at QUT's Faculty of Health and who co-authored the study, said disease atlases are helpful for showing patterns but rarely adjusted for anything beyond age and population size.

"People might be interested in considering whether for instance the distance to the nearest radiotherapy facility affects survival, or the proportion of workers with high sun exposure is associated with melanoma incidence," Dr Cramb said.

"Comparing socioeconomic associations with certain cancer types and with other countries worldwide is another potential area to investigate.

"This study unlocks data from sources like the Cancer Atlas to explore and refine research hypotheses."
-end-
Other researchers involved with the study included QUT Distinguished Professor Kerrie Mengersen, who is also Deputy Director of the ARC Centre of Excellence for Mathematical and Statistical Frontiers (ACEMS) based at QUT, Dr Earl Duncan and Professor Peter Baade from Cancer Council Queensland.

Queensland University of Technology

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.